These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6153209)

  • 21. A new immunization protocol for the production of monoclonal antibodies specific for VL subgroups of human immunoglobulins.
    Goto T; Abe M; Kosaka M
    Tokushima J Exp Med; 1990 Dec; 37(3-4):89-96. PubMed ID: 2128783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigens apparently nonimmunogenic for xid/Y mice cause the development of specific splenic plasmablasts and of fusion partners for SP2 cells giving hybridomas that secrete antibodies.
    Ohriner WD; Cebra JJ
    Eur J Immunol; 1985 Sep; 15(9):906-13. PubMed ID: 2412836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High frequency production of hybridomas secreting antibodies to cell antigens.
    Cianfriglia M; Nuti M; Turchi V; Barca S; Tombesi M; Morrone S; Cenciarelli C; Natali PG
    Hybridoma; 1987 Dec; 6(6):673-7. PubMed ID: 3501765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The optimal technological approach to the development of human hybridomas.
    Dorfman NA
    J Biol Response Mod; 1985 Jun; 4(3):213-39. PubMed ID: 2991473
    [No Abstract]   [Full Text] [Related]  

  • 25. [Production of antibodies against measles virus and HBs antigen by use of the mouse hybridoma technique (author's transl)].
    Togashi T; Kuwajima S; Takebayashi T; Itoh H; Kato T
    Uirusu; 1981 Dec; 31(2):145-52. PubMed ID: 7336577
    [No Abstract]   [Full Text] [Related]  

  • 26. Increased proportion of antigen-specific antibody-producing hybridomas following an in vitro immunization with in vivo immunized mouse spleen cells.
    Enriquez FJ; Bradley-Dunlop D; Joens L
    Hybridoma; 1991 Dec; 10(6):745-51. PubMed ID: 1816073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein.
    Freedman PM; Autry JR; Tokuda S; Williams RC
    J Natl Cancer Inst; 1976 Apr; 56(4):735-40. PubMed ID: 56452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro stimulation of immune spleen cells enhances the number of anti-lipid A-producing hybridomas.
    Erich T; Dekker B; De Beer M; Torensma R; Verhoef J
    J Immunol Methods; 1989 Mar; 118(1):17-24. PubMed ID: 2647854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of antigen presentation and exogenous cytokine activity during in vitro primary immunizations employed for the generation of monoclonal antibodies.
    Halabi G; McCullough KC
    J Immunol Methods; 1995 Oct; 186(2):205-16. PubMed ID: 7594620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-cross-reactive monoclonal antibodies to human chorionic gonadotropin generated after immunization with a synthetic peptide.
    Caraux J; Chichehian B; Gestin C; Longhi B; Lee AC; Powell JE; Stevens VC; Pourquier A
    J Immunol; 1985 Feb; 134(2):835-40. PubMed ID: 2578164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spleen cell analysis and optimal immunization for high-frequency production of specific hybridomas.
    Stähli C; Staehelin T; Miggiano V
    Methods Enzymol; 1983; 92():26-36. PubMed ID: 6304456
    [No Abstract]   [Full Text] [Related]  

  • 32. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas.
    Spieker-Polet H; Sethupathi P; Yam PC; Knight KL
    Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9348-52. PubMed ID: 7568130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of I region-restricted, antigen-specific T cell hybridomas to produce idiotypically specific anti-receptor antibodies.
    White J; Haskins KM; Marrack P; Kappler J
    J Immunol; 1983 Mar; 130(3):1033-7. PubMed ID: 6185566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hybridomas producing hemolytic plaques used to study the relationship between monoclonal antibody affinity and the efficiency of plaque inhibition with increasing concentrations of antigen.
    Bankert RB; Mazzaferro D; Mayers GL
    Hybridoma; 1981; 1(1):47-58. PubMed ID: 6765319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of mouse hybridomas by fusion of myeloma cells with lymphocytes derived from spleen, lymph node, and bone marrow.
    Başalp A; Yücel F
    Hybrid Hybridomics; 2003 Oct; 22(5):329-31. PubMed ID: 14678651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro immunization as an adjunct to the production of hybridomas producing antibodies against the lymphokine osteoclast activating factor.
    Luben RA; Mohler MA
    Mol Immunol; 1980 May; 17(5):635-9. PubMed ID: 7194419
    [No Abstract]   [Full Text] [Related]  

  • 37. Production of hybridomas secreting antibodies to the cornea.
    Zam ZS; Jones P; Das ND
    Curr Eye Res; 1981; 1(3):139-44. PubMed ID: 7297101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methods of enhancing the frequency of antigen-specific hybridomas.
    Siraganian RP; Fox PC; Berenstein EH
    Methods Enzymol; 1983; 92():17-26. PubMed ID: 6855610
    [No Abstract]   [Full Text] [Related]  

  • 39. Construction of antigen-specific suppressor T cell hybridomas from spleen cells of mice primed for the persistent IgE antibody formation.
    Iwata M; Ishizaka K
    J Immunol; 1988 Nov; 141(10):3270-7. PubMed ID: 2460527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colcemid treatment of myeloma prior to cell fusion increases the yield of hybridomas between myeloma and splenocyte.
    Miyahara M; Nakamura H; Hamaguchi Y
    Biochem Biophys Res Commun; 1984 Nov; 124(3):903-8. PubMed ID: 6508785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.